Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
- PMID: 27544765
- DOI: 10.1007/s00280-016-3137-0
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
Abstract
Purpose: Dihydropyrimidine dehydrogenase (DPD) is a critical determinant of 5-fluorouracil pharmacology, and reduced activity of DPD as a result of deleterious polymorphisms in the gene encoding DPD (DPYD) can result in severe treatment-related toxicity. Dosing recommendations to individualize treatment have been provided for three DPYD variants (DPYD*2A, c.2846A>T, and c.1679T>G). A fourth variant, c.1129-5923C>G/HapB3, has been shown to increase the risk of fluoropyrimidine-associated toxicity, but little is known about the functional effects of this variant.
Methods: By performing a large retrospective screen for DPYD variants, we identified three patients who were homozygous for c.1129-5923C>G/HapB3. We describe their clinical course of treatment and analyzed DPD activity and DPYD gene expression, to provide insight into the phenotypic effects of c.1129-5923C>G/HapB3.
Results: DPD activity could be measured in two patients and was 4.1 and 5.4 nmol/mg/h (DPD activity 41 and 55 % compared to controls, respectively). The fluoropyrimidine dose had to be reduced during treatment in both patients. In line with partial DPD deficiency in both patients, sequence analysis of DPD cDNA demonstrated a normal-sized (wild type) cDNA fragment of 486 bp, as well as a larger-sized (mutant) 530-bp fragment containing an aberrant 44-bp insertion in intron 10. Patient three tolerated treatment well, but DPD activity measurement was not possible as the patient had deceased at the time of performing the study.
Conclusions: The presented functional and clinical data indicate that the c.1129-5923C>G variant is both functionally and clinically relevant, and support an upfront dose reduction of the fluoropyrimidine starting dose in patients carrying c.1129-5923C>G homozygously.
Keywords: 5-Fluorouracil; Capecitabine; DPYD; Dihydropyrimidine dehydrogenase; Fluoropyrimidines; Toxicity.
Similar articles
-
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537
-
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Lancet Oncol. 2015. PMID: 26603945
-
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4. Int J Cancer. 2019. PMID: 30485432
-
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Bull Cancer. 2018. PMID: 29486921 Review. French.
-
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.Cancer Chemother Pharmacol. 2020 Jul;86(1):45-54. doi: 10.1007/s00280-020-04093-1. Epub 2020 Jun 11. Cancer Chemother Pharmacol. 2020. PMID: 32529295
Cited by
-
Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.Clin Pharmacol Ther. 2017 Oct;102(4):662-670. doi: 10.1002/cpt.685. Epub 2017 May 26. Clin Pharmacol Ther. 2017. PMID: 28295243 Free PMC article.
-
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.Cancer Drug Resist. 2019 Sep 19;2(3):787-802. doi: 10.20517/cdr.2018.006. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582578 Free PMC article. Review.
-
Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma.Front Pharmacol. 2018 Nov 15;9:1309. doi: 10.3389/fphar.2018.01309. eCollection 2018. Front Pharmacol. 2018. PMID: 30498448 Free PMC article.
-
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.Cancers (Basel). 2022 Jun 30;14(13):3207. doi: 10.3390/cancers14133207. Cancers (Basel). 2022. PMID: 35804978 Free PMC article. Review.
-
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project.J Mol Diagn. 2024 Oct;26(10):864-875. doi: 10.1016/j.jmoldx.2024.06.004. Epub 2024 Jul 18. J Mol Diagn. 2024. PMID: 39032822
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases